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Organic cationic transporter 3 (OCT3, SLS22A3) has only recently emerged as one of the regulators of monoaminergic
neurotransmission, which plays a critical role in the pathogenesis of depression and is a potential new antidepressant drug target.
OCT3 single-nucleotide polymorphisms (SNPs) have been investigated for their association with psychiatric disorders such as
methamphetamine use disorder and obsessive-compulsive disorder in children and adolescents, but not depression. This study
was designed to evaluate the allele frequencies of seven OCT3 SNPs in a US Caucasian depressed population and compare
these frequencies with a control group of nondepressed subjects. Informed consent and a DNA sample were obtained from 157
subjects and analysis was performed using real-time PCR. Allele and genotype frequencies were compared using a t-test and the
Pearson chi-square analysis, respectively. There were no signiﬁcant diﬀerences in OCT3 allele or genotype frequencies between the
depressed and non-depressed groups for all seven SNPs evaluated.
1.Introduction
Depression aﬀects up to 20% of the world population and
is one of the top ten causes of morbidity and mortality
worldwide [1]. Even though the precise neurobiological
processes causing depression are not yet completely under-
stood, it is certain that monoamine neurotransmission plays
an important role [2], as the vast majority of currently
available antidepressants alter serotonergic, noradrenergic,
and/or dopaminergic neurotransmission [3].
Monoamine neurotransmission is regulated by the
synaptic levels of neurotransmitters serotonin (5-HT), nore-
pinephrine (NE), and dopamine (DA). These levels are, in
turn, determined by the activity of monoamine transporters
[4]. Two uptake mechanisms are responsible for removal
of synaptic monoamines. The high-aﬃnity, low-capacity,
substrate-speciﬁc, and Na+-a n dC l −-dependent system
consists of serotonin (SERT), norepinephrine (NET), and
dopamine (DAT) transporters [4–6]. On the other hand, a
low-aﬃnity, high-capacity, multispeciﬁc, and Na+-a n dC l −-
independent system includes organic cation transporters
(OCT) 1, 2, and 3 (also known as solute carrier family 22
members 1–3, (SLC22A)1–3) [7]. All three OCTs are capable
of transporting multiple endogenous and exogenous organic
cations,including neurotransmitters 5-HT,NE, epinephrine,
DA, and histamine [7].
OCTs show a broad tissue distribution, with expression
in the CNS and peripheral tissues in both humans and
rodents [7]. While all three OCT subtypes are expressed
in the brain [7], OCT3 is preferentially expressed in brain
regions that belong to monoamine pathways, such as raphe
nuclei, striatum, ventral tegmental area, locus coeruleus,
hippocampus, and cortex [8–10], as well as the dorsomedial
hypothalamus which is the brain region involved in stress
regulation of monoamine neurotransmission [11, 12]. Con-
sidering the important role of stress in the pathogenesis of
depression [13], it is interesting that OCT3 is more sensitive
to inhibition by the stress hormone corticosterone than the
other two OCTs [12, 14–16].
The fact that OCT3 transports 5-HT, NE, and DA [7]
and is associated with monoamine pathways [8–10], points
towards OCT3playingaroleintheregulationofmonoamine
neurotransmission. Indeed, OCT3-deﬁcient mice show
altered monoamine neurotransmission [9, 17], anxiety-
related behavior [9, 18], stress response [9], and response to
psychostimulants [9]. Therefore, OCT3 could be a candidate2 ISRN Pharmacology
gene for association with neuropsychiatric disorders, such
as depression, where monoamine neurotransmission plays a
critical role.
Studies investigating the association of diﬀerent mono-
amine transporter gene polymorphisms with depression
have primarily focused on SERT and NET gene polymor-
phisms [19–23]. However, the association between OCT3
gene polymorphisms and depression has not been examined
so far. Recently, OCT3 gene single-nucleotide polymor-
phisms (SNPs) have been investigated for their association
with several psychiatric and nonpsychiatric disorders, such
as coronary artery disease [24], diabetic nephropathy, and
hypertension [25]. Psychiatric disorders examined so far
are methamphetamine use disorder [26] and obsessive-
compulsivedisorderinchildrenandadolescents[27],butnot
depression. Therefore, the goal of this study was to evaluate
seven OCT3 gene SNPs in a US Caucasian depressed pop-
ulation and compare these allele frequencies and resulting
genotypes with a control group of nondepressed subjects.
2. Methods
2.1. Subjects. This cross-sectional study utilized subjects
curr-ently being treated for depression at a community-
based psychiatric practice and an ambulatory care clinic
(depressed group). The nondepressed control group was
recruited from the same ambulatory care clinic and the
community. Subjects in the depressed group were identiﬁed
by either chart review or referred by their physician with
inclusion criteria of a documented diagnosis of depression
and no other Axis I or Axis II diagnosis. All self-reported as
Caucasian. Patients under the age of 18 years old or with
a concurrent diagnosis of bipolar disorder were excluded.
Subjects in the nondepressed (control) group were self-
r e f e r r e da n dr e p o r t e dn op r e v i o u sn o n p h a r m a c o l o g i co r
pharmacologic treatment of depression or bipolar disorder.
Allself-reportedasCaucasian.AxisIIdiagnosisinthecontrol
group was unknown. Subjects under the age of 18 years old
were also excluded from the control group. No other medical
comorbidity information was collected for either group. All
subjects signed an informed consent, and two cheek swab
samples were obtained for DNA collection. This study was
approved by the Shenandoah University Institutional Review
Board prior to its commencement.
2.2. Genotyping. Genomic DNA (gDNA) was isolated from
the cheek swab samples using a Qiagen QiaCube auto-
mated DNA isolation instrument (Qiagen Inc, Chatsworth,
Calif, USA) following the manufacturer’s protocol and then
frozen at −20◦C until the time of genotyping. A total of
seven OCT3 gene SNPs were selected for this study: SNP1
(rs1810126), SNP2 (rs204832), SNP3 (rs2048327), SNP4
(rs665185),SNP5(rs4709426),SNP6(rs3106164),andSNP7
(rs 2292334). SNPs 3, 4, 5, 6, and 7 have been previously
assessed for their correlation with methamphetamine use
disorder in a Japanese population [26] .S N P s1a n d7h a v e
been found to be present in Caucasian population [28]. In
addition,SNPs1,2,3,and7havebeenfoundtobeassociated
with reduced OCT3 mRNA levels in the human liver [29].
The genotyping was performed on an Applied Biosystems
7300 real-time PCR (Applied Biosystems, Foster City, Calif,
USA) with commercially available, validated TaqMan SNP
Genotyping Assays for OCT3 (Applied Biosystems, Foster
City, CA). The genotyping assays used included nonlabeled
primers and one wild-type and one variant allele-speciﬁc
ﬂuorescentTaqManlabeledoligonucleotideprobes.PCRwas
performed with a reaction volume of 10μL, which included
4.75μL of TaqMan Genotyping Master Mix (Applied Biosys-
tems), 0.5μL of 20x SNP Genotyping Assay, 3.75μLo fD E P C
H2O, and 1.0μL of gDNA. The PCR cycling conditions were
as follows: 1 cycle of 50◦Cf o r2m i n u t e s ,f o l l o w e db y1
cycle of 95◦C for 10 minutes, and 50 cycles of 92◦Cf o r
15 seconds and 60◦C for 90 seconds. Allelic discrimination
was evaluated by measuring endpoint ﬂuorescence intensity.
These results were analyzed with SDS software Version 1.3
(AppliedBiosystems),andthecorrespondinggenotypeswere
assigned.
2.3. Statistical Analysis. A power calculation was performed,
and it was estimated that 72 subjects would be required
in each group to detect a clinically signiﬁcant diﬀerence of
20% in each allele frequency, with a power of 80% and a
signiﬁcancelevelof5%.DeviationfromtheHardy-Weinberg
equilibrium was tested by allele counting and evaluated
by the chi-square (χ2) test. Allele frequencies were ﬁrst
evaluatedwithLevene’stestforequalityofvariancesandthen
compared between the two groups using the Student t-test.
GenotypeswerecomparedbetweengroupsusingthePearson
χ2 test. A P<0.05 was considered statistically signiﬁcant. All
statistical analyses were performed using PASW v18.0 (SPSS
Inc. Chicago, Il, USA).
3. Results
A total of 157 subjects were recruited into the study. There
were 82 subjects in the depressed group (28.6% males
and 71.4% females) and 75 subjects in the control group
(37.8% males and 62.2% females). The OCT3 genotype
frequenciesforallsevenSNPsexamineddidnotdeviatefrom
the Hardy-Weinberg equilibrium in either the depressed or
nondepressedcontrolgroup.Genotypeandallelefrequencies
for those seven SNPs in depressed patients and nondepressed
control subjects are summarized in Table 1. No signiﬁcant
diﬀerence was found in either genotype prevalence or allele
frequenciesbetweenthedepressedandnondepressedcontrol
groups (Table 1). In addition, this study found none of the
SNPsevaluatedtobeincompletelinkagedisequilibriumwith
one another.
4. Discussion
To the authors’ knowledge, this is the ﬁrst study to examine
the potential association of OCT3 gene polymorphisms with
depression. We evaluated the allele frequencies of seven
OCT3 gene SNPs in the US Caucasian patients actively being
treated for depression and compared these frequencies withISRN Pharmacology 3
Table 1: Genotype and allele distributions of OCT3 SNPs in depressed and nondepressed subjects.
SNP Sample Genotype Allele frequency
M/M M/m m/m P value M m P value
SNP1 Depressed 30 38 14 0.433 0.598 0.442 0.364
rs1810126 Control 26 30 19 0.547 0.453
SNP2 Depressed 29 39 14 0.442 0.591 0.409 0.425
rs2048327 Control 26 30 19 0.547 0.453
SNP3 Depressed 29 40 13 0.163 0.598 0.402 0.207
rs3088442 Control 25 29 21 0.527 0.473
SNP4 Depressed 21 44 17 0.737 0.524 0.476 0.694
rs665185 Control 23 36 16 0.547 0.453
SNP5 Depressed 22 42 18 0.954 0.524 0.476 0.783
rs4709426 Control 21 39 15 0.54 0.46
SNP6 Depressed 29 37 16 0.791 0.579 0.421 0.916
rs3106164 Control 28 30 17 0.573 0.427
SNP7 Depressed 30 38 14 0.403 0.598 0.402 0.430
rs2292334 Control 27 29 19 0.553 0.447
M: major allele; m: minor allele.
a control group of nondepressed subjects. No signiﬁcant dif-
ferencewasfoundinallelefrequenciesbetweenthedepressed
and nondepressed groups.
SNPs 3, 5, and 6 have been found to be associated
with methamphetamine dependence disorder in a Japanese
population [26]. That study found the major (M) allele
frequency in the control group to be 50.9% for SNP 3,
59.8% for SNP 5, and 69.1% for SNP 6. In our study, M
allele frequencies in the control group were 59.8% for SNP
3, 52.4% for SNP 5, and 57.3% for SNP 6. Lazar et al.
[28] examined OCT3 gene polymorphism in 100 Caucasian
individuals and found the frequency of the M allele to be
64% for SNP1 and 63.5% for SNP 7. Our ﬁndings for M
allele frequency in the control group are 54.7% for SNP 1
and 55.3% for SNP 7. Therefore, the M allele frequencies
we found in the US Caucasian population are relatively
consistent with frequencies found in diﬀerent geographic
and ethnic groups.
SNPs 1, 2, 3, and 7 have been found to be associated
with reduced OCT3 mRNA levels in the human liver [29].
However, at this point it is not known whether this translates
to reduced OCT3 mRNA levels or altered OCT3 function in
the brain for these particular SNPs. A recent study by Sakata
et al. [30] analyzed the functional properties of ﬁve OCT3
SNPs resulting in the amino acid changes using a transient
expression system. The study found decreased OCT3 uptake
capacity for three of those ﬁve SNPs tested. However, the
minor allele frequency for these three SNPs is extremely low
(less than 1%), which leads us not to pursue evaluation of
thesethreeSNPsatthistime.Obviously,furtherstudiesusing
these and additional SNPs are needed.
Several limitations of the present study should be noted.
First, with the sample size of 82 subjects in the depressed
group and 75 subjects in the control group, it is possible
to detect a diﬀerence of 20% in each allele frequency, but
not diﬀerences lower than 20%. Second, our study did
not include the data on the severity of depression in the
depressed group or the information on existence of other
medical comorbidities in either group.
Recently, OCT3 has received considerable attention in
regard to its role in the regulation of monoamine neuro-
transmission under both basal conditions [31] and during
stress [32, 33]. In addition, studies using animal models
of depression demonstrated antidepressant eﬀects of both
pharmacological [34] and antisense blockade [35]o fOCT3.
As treatment-resistant depression continues to present a
signiﬁcant clinical problem [36], and there is an ongoing
search for new antidepressant drugs, these data support the
notion of OCT3 as a potential new antidepressant therapy
target [31, 37].
In conclusion, this study is, to our knowledge, the ﬁrst to
compare the allele and genotype frequencies of seven OCT3
gene SNPs between a US Caucasian depressed population
and a control group of nondepressed subjects. No signiﬁcant
diﬀerence was found between these two groups for any of
the SNPs examined. However, further studies are needed to
verify these ﬁndings.
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